Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.
Shah
Manisha H
MH
Division of Hematology-Oncology, The Ohio State University, Columbus, Ohio 43210, USA. shah-2@medctr.osu.edu
Young
Donn
D
Kindler
Hedy L
HL
Webb
Iain
I
Kleiber
Barbara
B
Wright
John
J
Grever
Michael
M
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D002276:Carcinoid Tumor / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009362:Neoplasm Metastasis; D018358:Neuroendocrine Tumors / Q000188:drug therapy*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D011480:Protease Inhibitors / Q000627:therapeutic use*; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D001897:Boronic Acids; D011480:Protease Inhibitors; D061988:Proteasome Inhibitors; D011719:Pyrazines; D000069286:Bortezomib